Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Next Previous
Trial Profile

An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 3003891A (Primary) ; DTaP vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Acronyms RSV-F024
  • Sponsors GlaxoSmithKline Biologicals; GSK

Most Recent Events

  • 01 Feb 2018 Results (n=424) of pool data from two trials (NCT02360475 and NCT02753413) assessing the reactogenicity and immunogenicity of three different RSV-PreF formulations in non-pregnant women of childbearing age, were published in the Journal of Infectious Diseases.
  • 19 Jul 2016 Status changed from recruiting to completed.
  • 05 May 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top